openPR Logo
Press release

The Basic Information About Orlistat

According to statistics from the World Health Organization (WHO), nearly 2 billion people are overweight or obese worldwide. Every year, overweight or obesity causes 2.8 million deaths.

What 's Orlistat ?

Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was originally approved by the FDA in 1999 as the prescription drug Exenical, was approved in 2007 as the over-the-counter medication Alli. This drug is a generally well-tolerated and effective weight-loss aid.

What 's the mechanism of action?

Orlistat is a drug designed to treat obesity. It'sa potent and selective inhibitor of various lipase enzymes responsible for the metabolism of fat. It acts in the gastrointestinal (GI) tract via covalent binding to the serine residues located on the active site of both When orlistat is taken with food containing fat, it partially inhibits the enzymes of triglycerides. This decreases absorption of monoaclglycerides and free fatty acids, contributing to weight maintenance and weight loss.

What 's the side effects of the Orlistat ?

The main side effects of this drug are related to the gastrointestinal tract.

Abdominal pain or discomfort:
Oily discharge from the anus
Gas with oily anal discharge
Oily stools
More-frequent bowel movements
Urgent or hard-to-control bowel movements

Other possible side effects include:
Headache
Back pain
Upper respiratory infection

Huateng Pharma is a global supplier of pharmaceutical intermediates, PEG derivatives, investigateds, APIs and other chemical products. We are dedicated to supplying a wide range of pharmaceutical intermediates to serve customers in the world, such as anti-cancer series, anti-viral series We supply 3-Hexyltetrahydro-4-hydroxy-6-undecyl-2H-pyran-2-one (CAS NO.104801-96-9) with capacities varying from gram to kilograms, anti-diabetic series, antihypertensieve series and so on. It is used in preparation of Orlistat excipient F for quality control of Orlistat and its active pharmaceutical ingredient. This product is an intermediate of Orlistat and ready for mass production.

Hunan Huateng Pharmaceutical Co. Ltd.
Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China
Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China
Email: sales@huatengusa.com
Website: https://us.huatengsci.com
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818

Huateng Pharma is a leading and professional manufacturer which can provide pharmaceutical intermediates, PEG derivatives, biochemical reagents, APIs, Vitamin D Derivatives and so on. We are committed to providing cost-effective pharmaceutical products and services to customers around the world with the belief of "Strive for the Human Health".

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Basic Information About Orlistat here

News-ID: 2562262 • Views:

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Hunan Huateng Pharmaceutical to Exhibit Advanced PEG Derivatives and CDMO Solutions at CPHI China 2026
Hunan Huateng Pharmaceutical to Exhibit Advanced PEG Derivatives and CDMO Soluti …
Shanghai, China - June 2026 - Hunan Huateng Pharmaceutical Co., Ltd., a global supplier of PEG derivatives and CDMO partner for APIs and intermediates, announced its participation in CPHI China 2026, one of Asia's leading pharmaceutical industry exhibitions. The event will be held from June 16-18, 2026, at the Shanghai New International Expo Center (SNIEC) in Shanghai, China. Huateng Pharma will welcome pharmaceutical professionals, biotech innovators, sourcing specialists, and manufacturing partners
Huateng Pharma Supplies Minoxidil Intermediate 2,4-Diamino-6-chloropyrimidine (CAS NO.156-83-2)
Huateng Pharma Supplies Minoxidil Intermediate 2,4-Diamino-6-chloropyrimidine (C …
Minoxidil was first introduced by Upjohn Company of the United States, and was first used as an oral drug for the treatment of refractory hypertension in the 1970s. In later clinical applications, doctors observed hair regrowth and generalized excessive hair in balding patients, which led to the development of minoxidil preparations. Minoxidil can increase local blood supply, stimulate the proliferation and differentiation of hair follicle epithelial cells, so as to promote
Huateng Pharma Supplies Anti-diabetic API Intermediates With Huge Stock
Huateng Pharma Supplies Anti-diabetic API Intermediates With Huge Stock
Diabetes is a serious chronic disease characterized by elevated blood sugar concentrations associated with the effects of abnormal beta cell biology on insulin action. Diabetes occurs when the pancreas does not produce enough insulin or the body does not use the insulin it does produce efficiently. The most common forms of diabetes are type 1 diabetes and type 2 diabetes. Type 1 diabetes is characterized by insufficient insulin production and
Huateng Pharma Supplies Some Intermediates of CDK4/6 Inhibitors for Treatment of Advanced Breast Cancer
Huateng Pharma Supplies Some Intermediates of CDK4/6 Inhibitors for Treatment of …
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer - that is approximately 15% of all cancer deaths among women. While breast cancer rates are higher among women in more developed regions, rates are increasing in nearly every region globally. The majority

All 5 Releases


More Releases for Orlistat

Orlistat Market Overview, Key Trends, and Major Player Analysis
The global orlistat market is positioned for notable growth as the demand for effective obesity treatments continues to rise. As more individuals seek non-invasive options and healthcare providers emphasize weight management programs, orlistat is becoming increasingly important in combating obesity worldwide. Let's explore the market's future value, key players, emerging trends, and the primary segments defining this sector. Projected Growth and Market Size of the Orlistat Market by 2030 The orlistat
Orlistat Market Current Status and Future Prospects till 2033
Orlistat Market size was valued at USD 1.2 Billion in 2024 and is projected to reach USD 1.8 Billion by 2033, exhibiting a CAGR of 4.5% from 2026 to 2033. Orlistat Market Outlook and Investment Analysis Q1: What is the current market outlook for Orlistat? The global Orlistat market is witnessing steady growth, driven by increasing awareness of obesity and related health risks. As a popular weight-loss medication, Orlistat has been in demand
Orlistat Market | Exploring Current Trends and Growth Status for 2025
Orlistat Market Outlook and Investment Analysis What is the current market outlook for Orlistat? The global Orlistat market is witnessing steady growth, driven by increasing awareness of obesity and related health risks. As a popular weight-loss medication, Orlistat has been in demand due to the rising prevalence of obesity worldwide, with a significant uptick in healthcare spending for weight management solutions. According to various studies, the global obesity treatment market is expected
Major Force in the Orlistat Market 2025: Rising Obesity Rates And Their Impact O …
How Will the Orlistat Market Grow, and What Is the Projected Market Size? Over the past few years, the market size of orlistat has expanded significantly. The projection shows an increase from $3.03 billion in 2024 to $3.24 billion in 2025 with a compound annual growth rate (CAGR) of 6.7%. The increase in previous years could be due to factors like heightened knowledge about the health risks connected with obesity,
Orlistat Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Orlistat Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The global orlistat market has witnessed significant growth due to the rising prevalence of obesity and related health complications such as diabetes, hypertension, and cardiovascular diseases.
Orlistat Market Insights, Demand, Analysis, Share, Forecast: 2024-2033
"The Business Research Company recently released a comprehensive report on the Global Orlistat Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of